Atezolizumab Improved Overall Survival Across Subgroups With NSCLC

The PD-L1 inhibitor atezolizumab significantly improved overall survival compared with docetaxel across subgroups of patients with non –small-cell lung cancer.

Source: CancerNetwork - December 7, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Lung Cancer News Source Type: news